title: [Effects of ceftriaxone on severe infectious complications in hematological disorders. Tohkai Research Group on Infections in Hematological Disorders].
abstract: Ceftriaxone (CTRX), a new long acting antibiotic in the 3rd generation cephem group, was administered intravenously once or twice a day in daily doses of 1-6 g for at least 3 days to 86 patients with severe infections complicating hematopoietic disorders. Underlying diseases were acute leukemia in 41 cases, chronic leukemia in 3 cases, malignant lymphoma in 19 cases, myeloma in 7 cases and others. Most patients (55 cases) suffered from sepsis or suspected sepsis. As for efficacy rates classified by underlying diseases, the treatment was effective in 61.0% of patients with acute leukemia. As for efficacy rates classified by infections, the treatment was effective in 60.0% of patients with sepsis. No side effects were noted except rash in 2 patients. Abnormal hepatic functions were recognized in 3 patients but were not attributed to the agent in any case. The results indicate that CTRX is a safe and useful antibiotic for the treatment of severe infections accompanied by hematopoietic disorders.
authors.affiliation: 2nd Department of Internal Medicine, Medical School, Nagoya City University.
authors.forename: Y
authors.initials: Y
authors.lastname: Mitomo
authors.forename: M
authors.initials: M
authors.lastname: Nitta
authors.forename: H
authors.initials: H
authors.lastname: Kodama
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
authors.forename: K
authors.initials: K
authors.lastname: Ohara
authors.forename: O
authors.initials: O
authors.lastname: Kamiya
authors.forename: S
authors.initials: S
authors.lastname: Shirakawa
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic
chemical_list: D002443:Ceftriaxone